Sort   by:  
 Page size 
ProteomicsMig6 mediates adaptive and acquired resistance to ALK and ROS1 fusion kinase inhibition through feedback activation of EGFR: Cuto28
ALK and ROS1 fusions defines subsets of lung adenocarcinoma. Although ALK/ROS1 inhibitors improved therapeutic outcome of patients harboring those oncogenic fusions, complete responses were rare, and resistance eventually develops from the residual tumor. To under the mechanisms contributing to resi...
ORGANISM(S): Homo sapiens (Human) 
2023-09-12 | PXD036771 | Pride
Lung cancer Kinase inhibitor Anaplastic lymphoma kinase Drug resistance 
ProteomicsMig6 mediates adaptive and acquired resistance to ALK and ROS1 fusion kinase inhibition through feedback activation of EGFR: H3122
ALK and ROS1 fusions defines subsets of lung adenocarcinoma. Although ALK/ROS1 inhibitors improved therapeutic outcome of patients harboring those oncogenic fusions, complete responses were rare, and resistance eventually develops from the residual tumor. To under the mechanisms contributing to resi...
ORGANISM(S): Homo sapiens (Human) 
2023-09-12 | PXD036772 | Pride
Lung cancer Kinase inhibitor Anaplastic lymphoma kinase Drug resistance 
Sort   by:  
 Page size